FDA approves GSK's bepirovirsen as treatment for hepatitis B
On October 20, 2026, the US FDA approved GSK's Hibsago (bepirovirsen) as the first antisense oligonucleotide for treating chronic hepatitis B in adults without cirrhosis. The approval is significant as it targets patients who have been on antiviral therapy for at least six months and have suppressed HBV DNA and HBsAg levels. Phase 3 B-WELL trials indicated that 19-20% of patients achieved a functional cure after treatment, a notable improvement compared to placebo.
On October 20, 2026, the US Food and Drug Administration (FDA) granted approval for GSK's Hibsago (bepirovirsen), representing a significant advancement in treating chronic hepatitis B. This approval is particularly noteworthy as it introduces the first antisense oligonucleotide designated for adult patients without cirrhosis. These patients must have been on antiviral therapy for a minimum of six months, demonstrating suppressed HBV DNA and HBsAg levels of 3,000 IU/mL or lower. The approval of Hibsago marks a pivotal moment in hepatitis B management, focusing on achieving a functional cure rather than merely controlling the virus.
The historical context for this development lies in the long-standing challenges associated with chronic hepatitis B treatment. Traditional antiviral therapies primarily aim to suppress the virus but do not eliminate it from the body. Bepirovirsen's innovative mechanism targets the virus's genetic material, offering a new approach that could potentially lead to a complete functional cure. In Phase 3 B-WELL trials, outcomes showed that between 19-20% of patients experienced a functional cure, defined as having undetectable HBsAg and HBV DNA levels 24 weeks post-treatment cessation. This represents a remarkable leap from the 0% cure rate observed in placebo groups.
The implementation of Hibsago involved extensive clinical trials and collaboration among various stakeholders, including GSK researchers, healthcare professionals, and participating patients. The B-WELL trials were crucial in providing the necessary data to support the drug's efficacy and safety. The treatment regimen allows for self-administration after the initial dose, enhancing patient convenience and adherence. This approach not only empowers patients but also reflects a growing trend toward personalized medicine in chronic disease management.
Beyond the immediate medical benefits, the approval of bepirovirsen carries broader economic and social implications. By potentially offering a functional cure for chronic hepatitis B, this treatment could significantly reduce the long-term healthcare costs associated with managing the disease. Furthermore, it may improve the quality of life for patients, contributing to better overall public health outcomes. The ability to treat hepatitis B more effectively could also alleviate the burden on healthcare systems, particularly in regions with high prevalence rates.
Looking ahead, the approval of Hibsago sets the stage for future advancements in hepatitis B treatment. Researchers and healthcare providers are optimistic about the potential for similar therapies that could target other viral infections. The success of bepirovirsen may inspire further innovation in antisense oligonucleotide technology, fostering a new era in viral disease management. As the global health community continues to address hepatitis B, the significance of this approval cannot be understated, marking a hopeful milestone in the fight against chronic viral infections.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Liam covers climate solutions and the people helping the planet heal.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
